Lupin gets US FDA nod for lamotrigine tablets
This article was originally published in Scrip
Executive Summary
Lupin's US subsidiary has received final US FDA approval for its ANDA for lamotrigine 25mg, 100mg, 150mg and 200mg tablets, which are generic versions of GlaxoSmithKline's anticonvulsant, Lamictal tablets. Lupin's potential launch of its product comes well after Teva Pharmaceutical Industries introduced the first generic version of Lamictal tablets in 2008, following a settlement of patent litigation with GSK in February 2005. Under the settlement, GlaxoSmithKline granted Teva the exclusive right to manufacture and sell a generic version of Lamictal during the six-month paediatric exclusivity period, which ended on 22 January 2009. Lamictal tablets had sales of about $452 million for the 12 months ended March 2010, according to IMS Health. Teva launched lamotrigine chewable tablets (5mg and 25mg) in 2005, and the Indian company, Aurobindo Pharma, received final FDA approval for lamotrigine 5mg and 25mg chewable, dispersible tablets last November.
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet